About: Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation
Creator	Gosangi, Babina Alessandrino, Francesco Davids, Matthew Giardino, Angela Krajewski, Katherine Ramaiya, Nikhil Somarouthu, Bhanusupriya
Source	PMC
abstract	The last 5 years have been marked by profound innovation in the targeted treatment of chronic lymphocytic leukemia (CLL) and indolent lymphomas. Using CLL as a case study, we present a timeline and overview of the current treatment landscape for the radiologist, including an overview of clinical and radiological features of CLL, discussion of the targeted agents themselves, and the role of imaging in response and toxicity assessment. The goal is to familiarize the radiologist with multiple Food and Drug Administration (FDA)-approved targeted agents used in this setting and associated adverse events which are commonly observed in this patient population.
has issue date	2018-04-18(xsd:dateTime)
bibo:doi	10.1186/s40644-018-0146-8
bibo:pmid	29669600
has license	cc-by
sha1sum (hex)	2a5970d4f18f29aaced928ca1211f316d02b8b98
schema:url	https://doi.org/10.1186/s40644-018-0146-8
resource representing a document's title	Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation
has PubMed Central identifier	PMC5907417
has PubMed identifier	29669600
schema:publication	Cancer Imaging
resource representing a document's body	covid:2a5970d4f18f29aaced928ca1211f316d02b8b98#body_text
is schema:about of	named entity 'agents' named entity 'radiologist' named entity 'targeted therapy' named entity 'ADVERSE EVENTS' named entity 'LANDSCAPE' named entity 'DISCUSSION' named entity 'PROFOUND' named entity 'adverse events' named entity 'population' named entity 'lymphomas' named entity 'radiologist' named entity 'CLL' named entity 'adverse events' named entity 'radiologist' named entity 'chronic lymphocytic leukemia' named entity 'rituximab' named entity 'chlorambucil' named entity 'SLL' named entity 'lymphocytosis' named entity 'CLL' named entity 'lymph nodes' named entity 'antibody' named entity 'signaling pathway' named entity 'lymph nodes' named entity 'CECT' named entity 'Ibrutinib' named entity 'therapeutic agents' named entity 'chlorambucil' named entity 'upper respiratory tract infection' named entity 'CLL' named entity 'lung' named entity 'apoptosis' named entity 'antibodies' named entity 'first-line therapy' named entity 'fludarabine' named entity 'type II' named entity 'antibodies' named entity 'cell surface' named entity 'adenopathy' named entity 'ofatumumab' named entity 'CD20' named entity 'monoclonal antibody' named entity 'obinutuzumab' named entity 'Ibrutinib' named entity 'hepatitis' named entity 'somatic mutations' named entity 'splenomegaly' named entity 'SLL' named entity 'splenic' named entity 'fludarabine' named entity 'CLL' named entity 'abdomen' named entity 'ibrutinib' named entity 'Rituximab' named entity 'tissue sampling' named entity 'chromosome' named entity 'hepatosplenomegaly' named entity 'chlorambucil' named entity 'diffuse large B cell lymphoma' named entity 'CLL' named entity 'obinutuzumab' named entity 'ground glass opacities' named entity 'prognostic significance' named entity 'pectoral region' named entity 'chlorambucil' named entity 'biopsied' named entity 'FDA' named entity 'mediastinal mass' named entity 'monotherapy' named entity 'liver' named entity 'obinutuzumab' named entity 'SLL' named entity 'adverse events' named entity 'immunophenotype' named entity 'prognostic significance'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software